20 articles
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
Scientists discover how two microbes team up to accelerate colon cancer, but L-arginine may disrupt their deadly partnership.
A sweeping 2025 review maps how gut, tumor, and systemic microbiomes promote or suppress cancer across every major tumor type.
New research reveals how a common gut bacterium reprograms immune cells to accelerate colorectal cancer progression.
Fusobacterium nucleatum has shifted from suspected bystander to confirmed cancer driver — here's what the science reveals.
A newly discovered bacteriophage inside common gut bacteria appears strongly linked to colorectal cancer, potentially explaining a long-standing medical paradox.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A cancer patient on nivolumab developed Eikenella corrodens bacteremia after CNS infection, revealing how immune checkpoint therapy may enable dangerous microbial dissemination.
A tryptophan-derived gut metabolite suppresses colorectal cancer by blocking a key glycolysis enzyme via STAT3 inhibition.
Machine learning models achieve 88-97% accuracy in detecting gastric cancer risk through microbiome analysis, opening new paths for early detection.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
Specific gut microbes produce compounds that reprogram fat cells to enhance immune responses against cancer.
Specific gut bacteria enhance anti-PD-1 cancer treatment by converting immune cells into powerful tumor fighters.
Pre-treatment gut microbiome signatures predicted cancer recurrence in 674 melanoma patients receiving immune checkpoint blockade, with AUC up to 0.94.
Lactobacillus johnsonii bacteria enhances immune response and prevents liver cancer recurrence when combined with immunotherapy.
Researchers mapped distinct cell populations in human pancreatic ducts, finding two subtypes that drive aggressive, lower-survival pancreatic cancer.
Specific bacterial metabolic pathways in the gut determine whether cancer immunotherapy works by controlling immune responses.
Researchers uncover how cancer cells evade ADC therapy by suppressing drug uptake — and identify a drug target to reverse resistance.
A comprehensive review reveals how intracellular bacteria colonize cancer cells, fuel metastasis, and can be weaponized against tumors.
